Home › Head and Neck Squamous Cell Carcinoma › Michigan › Detroit
Head and Neck Squamous Cell Carcinoma clinical trials in Detroit, MI
15 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Detroit (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecruitingPhase 3
- Karmanos Cancer Institute, Detroit
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RecruitingPhase 1/2
- Karmanos Cancer Institute, Detroit
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RecruitingObservational study
- Karmanos Cancer Institute, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RecruitingPhase 2/3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of DM005 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Henry Ford Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RecruitingPhase 1
- Karmanos Cancer Institute, Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Henry Ford Health System, Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 129, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RecruitingPhase 1/2
- Karmanos Cancer Institute, Detroit
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- Nashville, TN39 studies
- New York City, NY39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Philadelphia, PA26 studies
- Chicago, IL26 studies
- Atlanta, GA24 studies
- San Antonio, TX22 studies
- Pittsburgh, PA22 studies
Other studies in Detroit
- Non-Small Cell Lung Cancer44 studies
- Breast Cancer33 studies
- Cancer (all types)29 studies
- Colorectal Cancer26 studies
- Ovarian Cancer26 studies
- Metastatic Cancer24 studies
- Prostate Cancer22 studies
- Endometrial Cancer21 studies
- Lung Cancer20 studies
- Multiple Myeloma19 studies
- Stomach Cancer16 studies
- Acute Myeloid Leukemia14 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.